{"name":"VERITY","slug":"verity","ticker":"","exchange":"","domain":"verity.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2000-01-01","label":"Trelstar first approved","drug":"Trelstar","drugSlug":"triptorelin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Trelstar","genericName":"triptorelin","slug":"triptorelin","indication":"Advanced Prostatic Carcinoma","status":"marketed"},{"name":"Bacillus Calmette-Guerin: Strain TICE","genericName":"Bacillus Calmette-Guerin: Strain TICE","slug":"bacillus-calmette-guerin-strain-tice","indication":"Non-muscle invasive bladder cancer (NMIBC)","status":"phase_3"}]}],"pipeline":[{"name":"Trelstar","genericName":"triptorelin","slug":"triptorelin","phase":"marketed","mechanism":"Trelstar works by binding to and activating the gonadotropin-releasing hormone receptor, which leads to a decrease in testosterone production.","indications":["Advanced Prostatic Carcinoma"],"catalyst":""},{"name":"Bacillus Calmette-Guerin: Strain TICE","genericName":"Bacillus Calmette-Guerin: Strain TICE","slug":"bacillus-calmette-guerin-strain-tice","phase":"phase_3","mechanism":"BCG TICE is a live attenuated mycobacterial vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.","indications":["Non-muscle invasive bladder cancer (NMIBC)","Potentially other solid tumors (investigational)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}